Understanding the long-term effects of treated neurocysticercosis
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
National Institutes of Health Clinical Center (CC) · NCT00001205
This study is looking at how people with neurocysticercosis do over time after treatment to see what affects their long-term health and to find better ways to diagnose and understand the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 3 Years to 99 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) (nih) |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00001205 on ClinicalTrials.gov |
What this trial studies
This observational study follows patients diagnosed with neurocysticercosis, a brain disease caused by the pork tapeworm, to assess the clinical and biological factors influencing their long-term outcomes after treatment. Participants will receive standard anthelmintic therapy and anti-inflammatories, and their progress will be monitored over time. The study aims to develop novel biomarkers, improve diagnostic methods, and explore the interactions between the host and the parasite. By collecting clinical data and biological samples, researchers hope to better understand the disease's course and its various manifestations.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 3 years and older with proven or likely neurocysticercosis.
Not a fit: Patients without a diagnosis of neurocysticercosis or those under 3 years of age may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better long-term outcomes for patients with neurocysticercosis.
How similar studies have performed: While there have been studies on neurocysticercosis, this approach focusing on long-term outcomes and biomarker development is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Arms 1-5 (NCC): 1. Aged 3 years and older. 2. Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document. 3. Patients with proven or likely NCC Arm 6 (Endemic Exposures): 1. Patient with epidemiologic history compatible with possible exposure to NCC 2. Aged 18 years and older. EXCLUSION CRITERIA: Not applicable
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Elise M O'Connell, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Perla M Adames Castillo, R.N.
- Email: perla.adamescastillo@nih.gov
- Phone: (301) 402-8495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cysticercosis, Neurocysticercosis, Tapeworm, Taenia Solium, Natural History, Seizures, Aseptic Meningitis, Hydrocephalus